Journals / Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi / 2022 / Cilt: 17 - Sayı: 1

The Effectiveness and Reliability of Intravitreal Bevacizumab in Neovascular Glaucoma

Neovasküler Glokomda İntravitreal Bevacizumabın Etkinliği ve Güvenilirliği

Pages
156–162
Publication Date
2022-03-21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, methods that permanently inhibit VEGF secretion such as panretinal photocoagulation should also be included in the treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the effectiveness and reliability of intravitreal bevacizumab in patients with neovascular glaucoma.
📊
Key Findings & Data:Material and Methods: Twenty-three eyes of 20 patients who underwent intravitreal bevacizumab for the treatment of neovascular glaucoma in the ophthalmology clinic of Ankara Numune Training and Research Hospital and were followed for at least 4 months were retrospectively evaluated.
💡
Conclusion & Impact:However, methods that permanently inhibit VEGF secretion such as panretinal photocoagulation should also be included in the treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Neovasküler glokom · bevacizumab · intravitreal enjeksiyon

Abstract

Objective: To evaluate the effectiveness and reliability of intravitreal bevacizumab in patients with neovascular glaucoma. Material and Methods: Twenty-three eyes of 20 patients who underwent intravitreal bevacizumab for the treatment of neovascular glaucoma in the ophthalmology clinic of Ankara Numune Training and Research Hospital and were followed for at least 4 months were retrospectively evaluated. Anterior segments were compared using color image and anterior segment fluorescein angiography before and after injection. Intravitreal bevacizumab of 1.25 mg/0.05 ml was administered to patients who received maximum antiglaucomatous medication prior to the injection. The patients were followed-up on the first day, at the first week, at the first month and then monthly Results: Of the 20 patients included in the study, 8 were female and 12 were male. The mean age was 65,13+ 12,31 (24-87) years. The mean follow-up period was 7.44+ 2.99 (4-10) months. Prior to the injection, 13 eyes (56.52%) underwent panretinal photocoagulation (PRP); 2 eyes (8,69%) cyclocryotherapy; and 1 eye (4,34%) post-operative cryotherapy. In all patients, significant regression of neovascularization was observed in iris and iridocorneal angle within 24 hours after one or two injections. It totally disappeared in 10 eyes (%43,47), including two eyes (%8,69) within 1 week, 8 eyes (%34.78) within 4-6 weeks. Conclusion: Intravitreal bevacizumab injection is an effective method for regressing anterior segment neovascularization. However, methods that permanently inhibit VEGF secretion such as panretinal photocoagulation should also be included in the treatment.

Özet

Amaç: Neovasküler Glokomlu olgularda intravitreal bevacizumabın etkinliğini ve güvenilirliğini değerlendirmektir. Gereç ve Yöntemler: Kliniğimizde neovasküler glokom tanısıyla intravitreal bevacizumab uygulanan ve en az 4 ay takip edilen 20 hastanın 23 gözü retrospektif olarak değerlendirildi. Enjeksiyon öncesinde ve sonrasında ön segment renkli resim ve ön segment floresein anjiyografi çekilerek karşılaştırıldı. Enjeksiyon öncesinde maksimum antiglokomatöz medikal tedavi verilen hastalara intravitreal 1,25 mg / 0,05 ml bevacizumab uygulandı. Hastalar enjeksiyon sonrası birinci gün, birinci hafta, birinci ayda ve sonrasında aylık kontroller ile takip edildi. Bulgular: Çalışmaya alınan 20 hastanın 8’i kadın, 12’si erkekti. Ortalama yaş 65,13+12,31 (24-87 ) yıldı. Ortalama takip süresi 7,44+ 2.99 ( 4-10 ) aydı. Enjeksiyon öncesinde 13 (%56,52) göze panretinal fotokoagulasyon (PRP), 2 (%8,69) göze siklokrioterapi, 1 (%4,34) göze postekvatoryal krioterapi uygulandı. Tüm hastalarda bir ya da iki enjeksiyon sonrasında 24 saat içinde iris ve açı neovaskülarizasyonunda belirgin gerileme tespit edildi .İki (%8,69) gözde 1. haftada, 8 (%34,78) gözde 4-6 hafta içinde olmak üzere 10 (% 43,47 ) gözde tamamen kayboldu. Sonuç: İntravitreal bevacizumab enjeksiyonu ön segment neovaskülarizasyonunu geriletmek için etkili bir yöntemdir. Ancak panretinal fotokoagülasyon gibi VEGF salınımı kalıcı olarak inhibe eden yöntemler de tedaviye mutlaka eklenmelidir.

🔖

Cite This Article

ÇOMÇALI, S., ÖNEN, M., KEMER, Ö. E., YAZAR, Z. (2022). The Effectiveness and Reliability of Intravitreal Bevacizumab in Neovascular Glaucoma. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, Cilt: 17 - Sayı: 1, 156–162. https://ajindex.com/articles/783174

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Yanoff M, Duker JS. Ophthalmology. Second Edition. Part 12. Chapter 225. Maher MF. Neovascular glaucoma. 2004
  2. 511 2. Sivak-Callcott JA, O’Day DM, Gass JD, et al.: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.Ophthalmology.2001
  3. 1776 3. Keklikci U,Ciftci S, Unlu K.:The Association of Vascular Endothelial Growth Factor and Neovascular Glaucoma and the Role of Anti-Vascular Endothelial Growth Factor in Treatment:Review Turkiye Klinikleri J Ophtalmol 2008
  4. 131 4. Wand M, Dueker DK, Aiello LM,et al.: Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization and neovascular glaucoma.Am J Ophtalmol.1978
  5. Yazdani S, Hendi K, Pakravan M.:Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007
  6. Wasik A, Song HF, Grimes A, et al.:Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma.Optometry.2009
  7. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil and leucovorinfor metastatic colorectal cancer.N Engl J Med.2004
  8. 2342 8. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006
  9. Bayar SA, Küçükerdönmez C, Adıbelli FM, Suveren EH, Yılmaz G, Akman A, Akova YA. Neovasküler Glokom Tedavisinde İntravitreal Bevacizumab Uygulamasının Uzun Dönemdeki Etkinliği. Glo-Kat 2009
  10. 215 10. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab in the treatment of neovascular glaucoma. Am J Ophthalmol 2006
  11. Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal arter occlusion. Eur J Ophthalmol 2007
  12. Batıoğlu F, Astam N, Özmert E. Santral Retinal Ven Tıkanıklığına Bağlı Neovasküler Glokomda İntravitreal Bevacizumabın Etkinliği. Retina-Vitreus 2007
  13. Grisanti S, Biester S, Peters S,Tatar O, Ziemssen F, Bartz-Schmidt KU, for the Tuebingen Bevacizumab Study Group. İntracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006
  14. Rasier R, Artunay Ö, Yüzbaşıoğlu E, Şengül A, Bahçecioğlu H.Neovasküler Glokomlu Olguda Eş zamanlı İntravitreal ve İntrakameral Bevacizumab Uygulaması. Glokom-Katarakt 2008
  15. 2 15. Karadağ R, Aydın B, Hepşen İF. Seton Cerrahis